Jonathan A Phillips (Jonathan Phillips)

Years Active: 2020-2022
Publications (10 Years): 4

Intellia Therapeutics Inc

University of Massachusetts (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Intellia Therapeutics Inc Apr 22 2019

United States

Senior Director :: Toxicology

Vertex Pharmaceuticals Inc Sep 01 2016 - Apr 12 2019

United States

Fellow :: Toxicology

Boehringer Ingelheim Pharmaceuticals Inc

United States

Senior Principal Scientist :: Nonclinical Drug Safety

NASA Ames Research Center

United States

NASA postdoctoral fellow :: Gravitational Biology

Education History

University of Massachusetts

United States

PHD :: Cell Biology

Florida Institute of Technology

United States

BSC :: Biology

Publications

Jonathan A Phillips, Mitchell E Taub, Matthew S Bogdanffy, Jing Yuan, Brian Knight, James D Smith, Warren W Ku
Mode of action and human relevance assessment of male CD-1 mouse renal adenocarcinoma associated with lifetime exposure to empagliflozin. Journal of applied toxicology : JAT 42 (10) (2022)
Julian D Gillmore, Ed Gane, Jorg Taubel, Justin Kao, Marianna Fontana, Michael L Maitland, Jessica Seitzer, Daniel O'Connell, Kathryn R Walsh, Kristy Wood, Jonathan A Phillips, Yuanxin Xu, Adam Amaral, Adam P Boyd, Jeffrey E Cehelsky, Mark D McKee, Andrew Schiermeier, Olivier Harari, Andrew Murphy, Christos A Kyratsous, Brian Zambrowicz, Randy Soltys, David E Gutstein, John Leonard, Laura Sepp-Lorenzino, David Lebwohl
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis. The New England journal of medicine 385 (6) (2021)
Stephen Fowler, Wen Li Kelly Chen, David B Duignan, Anshul Gupta, Niresh Hariparsad, Jane R Kenny, W George Lai, Jennifer Liras, Jonathan A Phillips, Jinping Gan
Microphysiological systems for ADME-related applications: current status and recommendations for system development and characterization. Lab on a chip 20 (3) (2020)
Jonathan A Phillips, Taraka Sai Pavan Grandhi, Myrtle Davis, Jean-Charles Gautier, Niresh Hariparsad, Douglas Keller, Radhakrishna Sura, Terry R Van Vleet
A pharmaceutical industry perspective on microphysiological kidney systems for evaluation of safety for new therapies. Lab on a chip 20 (3) (2020)

Jonathan A Phillips.css-eqlu8i{font-size:small;padding-left:4px;} (Jonathan Phillips)